Eden vs LillyDirect (Zepbound) (2026): prices, structure, verdict

On tirzepatide, Eden is cheaper: $408 versus $449 a month all-in — a $41 monthly gap, $492 across a year of maintenance dosing.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

On semaglutide, only Eden has a rankable figure: $198 a month all-in; LillyDirect (Zepbound)↗ does not offer semaglutide.

§ Side by side

§ Each record, read aloud

The two records, condensed

Eden: the record, condensed

Start with the load-bearing figure: $408 a month, all-in, is what Eden charges for tirzepatide at the 10 mg basis. The structure is tiered: the advertised entry point is $348, but the maintenance figure — the one a full year is actually billed at — is $408. That $60 gap between the ad and the anniversary is the single most important line in this record.

The all-in figure already contains a compulsory $99 monthly membership. That is the honest way to quote it: a bundled price is only misleading when its parts are advertised separately, and here the medication-only $309 would be exactly that kind of mirage.

Context for that figure: it ranks #16 of 17 in the verified tirzepatide index — $193/month above the floor (NexLife↗, $215) — and sits $41 under the brand benchmark (Zepbound (LillyDirect), $449 at maintenance). Annualized, a monthly-billed year here runs $4,896.

Start with the load-bearing figure: $198 a month, all-in, is what Eden charges for semaglutide at the 2.4 mg basis. Because pricing is flat across the ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg), a dose increase at Eden is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

A required $99/month membership is part of the deal, and part of the figure above: $99 of medication plus $99 of platform equals the $198 that leaves your account. Judge the membership by what it includes, but compare on the total.

To place the number: #10 of 20 verified programs, with the floor $65/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare↗)) sits at $349, so the compounded case here is worth $151 a month. A year at this figure: $2,376 monthly-billed.

Operationally at Eden: shipping included; commitment membership auto-renews; cancellation membership auto-renews until cancelled; pharmacy not publicly named — ask in writing before paying; states: most states; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the Eden page · visit Eden ↗

LillyDirect (Zepbound): the record, condensed

On tirzepatide, the number that matters at LillyDirect (Zepbound) is $449 a month all-in — the figure at the 10 mg maintenance basis this whole site ranks on. The structure is tiered: the advertised entry point is $299, but the maintenance figure — the one a full year is actually billed at — is $449. That $150 gap between the ad and the anniversary is the single most important line in this record.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $449 is the whole subscription, which makes LillyDirect (Zepbound) unusually easy to compare and unusually easy to leave.

Context for that figure: it ranks #0 of 17 in the verified tirzepatide index — $234/month above the floor (NexLife, $215) — and sits $0 over the brand benchmark (Zepbound (LillyDirect), $449 at maintenance). Annualized, a monthly-billed year here runs $5,388.

Operationally at LillyDirect (Zepbound): shipping included (or same-day retail pickup); commitment 45-day refill cadence to keep pricing; cancellation no subscription; refill-window rules apply; pharmacy named (Eli Lilly direct / retail partners); states: 50 states; evidence source-verified, captured 2026-08-09. The full record with source and archive links: the LillyDirect (Zepbound) page · visit LillyDirect (Zepbound) ↗

Tirzepatide: the duel in full

The tirzepatide arithmetic between these two is short: $408 (Eden) against $449 (LillyDirect (Zepbound)). $41 a month sounds survivable; $492 a year is a decision.

Eden’s total includes a mandatory $99/month membership; LillyDirect (Zepbound) has none. The all-in figures above neutralize that difference — but the membership side has an exit consideration the other lacks: a fee that recurs until you affirmatively cancel it.

Translate the $41/month spread into medication: $492 a year equals roughly 1.2 months of therapy at the cheaper program’s rate. That is the honest unit for gaps in this market — months of treatment, not abstract dollars — and it is why small-looking monthly differences decide long courses.

On best published rate — the lower of each program’s month-to-month price and its labeled 12-month-plan rate, which is the sort most price roundups quietly run — the duel reads: Eden $408/mo month-to-month versus LillyDirect (Zepbound) $449/mo month-to-month. Same winner on both bases — Eden leads whether you compare month-to-month prices or committed-plan rates, which makes this one of the cleaner verdicts in the index. Prepaid rates are upfront commitments with refund terms to verify before they count.

§ The clock, run forward

Three, six, twelve, twenty-four months — best path each way

3 months: Eden $1,224 monthly; LillyDirect (Zepbound) $1,347 monthly — best path favors Eden by $123. 6 months: Eden $2,448 monthly; LillyDirect (Zepbound) $2,694 monthly — best path favors Eden by $246. 12 months: Eden $4,896 monthly; LillyDirect (Zepbound) $5,388 monthly — best path favors Eden by $492. 24 months: Eden $9,792 monthly; LillyDirect (Zepbound) $10,776 monthly — best path favors Eden by $984.

Prepaid paths above are billed upfront and assume the published rate holds (the 24-month figures extend the 12-month rate, an assumption worth naming). The honest reading: over short horizons the monthly gap decides; over long horizons the prepaid ladders and structural traps (dose tiers, memberships) take over — which is exactly the split the verdict section below scores.

§ Structure vs structure

Everything besides the price

Coverage: Eden publishes “most states”; LillyDirect (Zepbound) publishes “50 states” — for anything short of an explicit 50-state claim, intake is the final word.

Pharmacy transparency splits them: LillyDirect (Zepbound) names its network (Eli Lilly direct / retail partners); Eden does not, which shifts the burden of verification onto your intake questions.

Exit terms: Eden — membership auto-renews; membership auto-renews until cancelled. LillyDirect (Zepbound) — 45-day refill cadence to keep pricing; no subscription; refill-window rules apply.

Evidence: Eden source-verified (captured 2026-08-05); LillyDirect (Zepbound) source-verified (2026-08-09).

A rule that has held across this index: disclosure predicts disclosure. Whichever of these two publishes more — pharmacies, states, exit terms — is usually the one whose invoice matches its ad.

§ If you move

Switching between Eden and LillyDirect (Zepbound)

Prescriptions do not transfer like phone numbers: moving in either direction means completing the destination’s intake and having its prescriber write a new patient-specific prescription. The mechanics that prevent a bad month: confirm the destination serves your state and quotes your current dose in writing before cancelling anything; time the first new shipment to overlap the last old one rather than gap it; cancel the origin per its published terms (Eden: membership auto-renews until cancelled; LillyDirect (Zepbound): no subscription; refill-window rules apply) and screenshot the confirmation; and never leave a prepaid balance stranded — which is the standing argument for prepaying only after a program has already earned a few monthly cycles.

§ Verdict by situation

Which one, for whom

§ More pairings